DOI QR코드

DOI QR Code

Concurrent Use of Sulfonylureas and Antimicrobials of the Elderly in Korea: A Potential Risk of Hypoglycemia

고령자에서 Sulfonylureas와 항균제의 병용투여 현황

  • Lee, Sera (College of Pharmacy, Sookmyung Women's University) ;
  • Ock, Miyoung (College of Pharmacy, Sookmyung Women's University) ;
  • Kim, Hyunah (College of Pharmacy, Sookmyung Women's University)
  • 이세라 (숙명여자대학교 약학대학) ;
  • 옥미영 (숙명여자대학교 약학대학) ;
  • 김현아 (숙명여자대학교 약학대학)
  • Received : 2018.07.05
  • Accepted : 2018.09.10
  • Published : 2018.09.03

Abstract

Background: Previous studies have noted that the simultaneous use of sulfonylureas and antimicrobials, which is common, could increase the risk of hypoglycemia. In particular, an age of 65 years or older is a known risk factor for sulfonylurea-related hypoglycemia in hospitalized patients. Therefore, we performed this study to determine the potential risk of hypoglycemia from the concurrent use of antimicrobials and sulfonylureas. Methods: We performed a cross-sectional study on the National Health Insurance Service-National Sample Cohort from 2013. The eligibility criteria included patients of 65 years of age or older taking a sulfonylurea with 25 different antimicrobials. Different risk ratings of severity in drug-drug interactions (potential DDIs), level X, D, or C in Lexi-$Interact^{TM}$ online, and contraindicated, major, or moderate severity level in $Micromedex^{(R)}$ were included. SAS version 9.4 was used for data analysis. Results: A total of 6,006 elderly patients with 25,613 prescriptions were included. The largest age group was 70 to 74 (32.7%), and 39.7% of patients were men. The mean number of prescriptions was 4.3 per patient. The most frequently used antimicrobials were levofloxacin (6,583, 25.7%), ofloxacin (6,549, 25.6%), fluconazole (4,678, 18.0%), and ciprofloxacin (2,551, 9.8%). Among sulfonylureas, glimepiride was prescribed most frequently, followed by gliclazide, glibenclamide, and glipizide. Conclusion: Of the antimicrobials with a high potential of hypoglycemia, levofloxacin, ofloxacin, fluconazole, and ciprofloxacin were used frequently. Thus, the monitoring of clinically relevant interactions is required for patients concurrently administered sulfonylureas and antimicrobials.

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96. https://doi.org/10.1007/s00125-012-2534-0
  2. Statistics Korea: 2016 statistical results about cause of death. Available at http://www.index.go.kr. Accessed July 03, 2018.
  3. Korbel L, Spencer JD. Diabetes mellitus and infection: an evaluation of hospital utilization and management costs in the United States. Journal of diabetes and its complications 2015;29:192-5. https://doi.org/10.1016/j.jdiacomp.2014.11.005
  4. Peleg AY et al. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes/metabolism research and reviews 2007;23:3-13. https://doi.org/10.1002/dmrr.682
  5. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). Pathogens and Disease 1999;26:256-65.
  6. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005;41:281-8. https://doi.org/10.1086/431587
  7. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 2012; 16(Suppl1):S27-36. https://doi.org/10.4103/2230-8210.94253
  8. Lee YS, Lee JS, Lee SH. Analysis of drug interaction information. Korean J Clin Pharm 2009;19:1-17.
  9. Samardzic I, Bacic-Vrca V. Incidence of potential drug-drug interactions with antidiabetic drugs. Pharmazie 2015;70:410-5.
  10. Triplitt C. Drug Interactions of Medications Commonly Used in Diabetes. Diabetes Spectrum 2006;19:202-11. https://doi.org/10.2337/diaspect.19.4.202
  11. Lindley CM, Tully MP, Paramsothy V, Tallis RC. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing 1992;21:294-300. https://doi.org/10.1093/ageing/21.4.294
  12. Lee J, Lee JS, Park SH, et al. Cohort Profile: The national health insurance service-national sample cohort (NHIS-NSC), South Korea. Int J Epidemiol 2017;46:e15.
  13. Lexicomp. Drugs interactions. Wolters Kluwer Health, Philadelphia, Pennsylvania, USA., 2018. Available from http://www.lexi.com/ online. Accessed July 03, 2018.
  14. MicroMedex Truven Health Analytics. Micromedex 2.0: Drug interactions (electronic version). Greenwood Village, Colorado, USA, 2018. Available from http://www.micromedexsolutions.com. Accessed July 03, 2018.
  15. Tan A, Holmes HM, Kuo YF, et al. Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use. J Gerontol A Biol Sci Med Sci 2015;70(2):247-54. https://doi.org/10.1093/gerona/glu072
  16. Parekh TM, Raji M, Lin YL, et al. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Intern Med 2014;174(10):1605-12. https://doi.org/10.1001/jamainternmed.2014.3293
  17. Carr R, Zed PJ. Octreotide for sulfonylurea-induced hypoglycemia following overdose. Ann Pharmacother 2002;36(11):1727-32. https://doi.org/10.1345/aph.1C076
  18. Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005;41(9):1269-76. https://doi.org/10.1086/496929
  19. Gajjar DA et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000;20(6 Pt 2):76S-86S. https://doi.org/10.1592/phco.20.8.76S.35182
  20. Park-Wyllie LY et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354(13):1352-61. https://doi.org/10.1056/NEJMoa055191
  21. Product Information: TEQUIN(R) (gatifloxacin) Tablets, Injection (2004), Bristol-Myers Squibb Company Princeton, NJ 08543 USA , Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21061s023,024,21062s026,037lbl.pdf. Accessed August 13, 2018.
  22. Hong EG. Drug Therapy of Elderly Diabetic Patients. Korean J Med 2011;80:635-42.
  23. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41. https://doi.org/10.1016/S0895-4356(97)00024-3
  24. Holstein A, Plaschke A, Hammer C, et al. Characteristics and time course of severe glimepiride-versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 2003;59:91-7. https://doi.org/10.1007/s00228-003-0592-4
  25. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:405-14. https://doi.org/10.1055/s-2003-44287
  26. El Ghandour S, Azar ST. Dysglycemia associated with quinolones. Prim Care Diabetes 2015;9:168-71. https://doi.org/10.1016/j.pcd.2014.10.006
  27. Dear Healthcare Professional/Pharmacist Letter. Ministry of Food and Drug Safety, Seoul, Korea. Available from http://www.mfds.go.kr/brd/m_545/view.do?seq=279&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&com-pany_nm=&page=1. Accessed August 14, 2018.
  28. Schelleman H, Bilker WB, Brensinger CM, et al. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther 2010;88:214-22. https://doi.org/10.1038/clpt.2010.74
  29. Andre F, Peter F, Martin C. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol 2016;10:2433-41. https://doi.org/10.2147/OPTH.S118409
  30. Lee JW, Woo SY, Park SJ, et al. Clostridium difficile Colitis after Topical Ophthalmic Use of Levofloxacin. Ewha Med J 2013;36(Suppl):S5-S8. https://doi.org/10.12771/emj.2013.36.S.S5
  31. Actavis. Package leaflet: Information for the patient; Levofloxacin 5mg/ml Eye Drops Solution. Actavis, Barnstaple, EX32 8NS, UK, 2018. Available at https://www.medicines.org.uk/emc/files/pil.7357.pdf. Accessed July 03, 2018.
  32. Allergan Pharmaceuticals Ireland. PACKAGE LEAFLET: INFORMATION FOR THE USER Exocin: ofloxacin 0.3% w/v eye drops, solution. Allergan Pharmaceuticals Ireland, Westport, Co. Mayo, Ireland, 2018. Available from http://www.hpra.ie/img/uploaded/swedocuments/2132153.PA0148_049_001.ec052f90-b0e7-414f-8476-61ea0b4f5da7.000001Product%20Leaflet%20Approved.131121.pdf. Accessed July 05, 2018.
  33. Kilbridge PM, Campbell UC, Cozart HB, et al. Automated surveillance for adverse drug events at a community hospital and an academic medical center. J Am Med Inform Assoc 2006;13:372-7. https://doi.org/10.1197/jamia.M2069
  34. Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care 2002;25:2109-10. https://doi.org/10.2337/diacare.25.11.2109
  35. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-12. https://doi.org/10.2337/diacare.26.6.1902
  36. Daniele S. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015;11:840-8.
  37. Vestal RE. Drug use in the elderly: a review of problems and special considerations. Drugs 1978;16:358. https://doi.org/10.2165/00003495-197816040-00004